# FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application

> **NCT06270394** · NA · COMPLETED · sponsor: **The First Affiliated Hospital of Anhui Medical University** · enrollment: 22 (actual)

## Conditions studied

- Malignant Tumors
- Positron-Emission Tomography

## Interventions

- **DRUG:** 68Ga-Fibroblast activation protein inhibitor

## Key facts

- **NCT ID:** NCT06270394
- **Lead sponsor:** The First Affiliated Hospital of Anhui Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-28
- **Primary completion:** 2023-11-28
- **Final completion:** 2025-05-31
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06270394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06270394, "FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06270394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*